Association of Genetic Polymorphisms with Response to Bevacizumab for Neovascular Age-related Macular Degeneration in the Chinese Population
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
AIMS: To determine whether there is an association between CFH, ARMS2, HTRA1, VEGF, SERPING1 or C3 genotypes and patient response to treatment with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD). MATERIALS & METHODS: This was a multicenter prospective study. One hundred and forty four patients with neovascular AMD treated with bevacizumab were recruited from 13 centers. Twelve SNPs were genotyped using Sequenom. Visual acuity score (VAS), central retinal thickness and maximum thickness of lesion were measured at each visit. RESULTS: For the CFH rs800292 polymorphism, mean VAS changes were 4.4, 8.7 and 15.5 letters in the CC, CT and TT genotype carriers (p = 0.009). For ARMS2 rs10490924, mean VAS changes were 3.6, 12.1 and 9.6 letters for the TT, TG and GG genotypes (p = 0.001). For HTRA1 rs11200638, mean VAS changes were 3.6, 12.3 and 9.6 letters for the AA, AG and GG genotypes (p < 0.001). CONCLUSION: CFH, ARMS2 and HTRA1 genotypes may influence patient response to treatment with intravitreal bevacizumab for neovascular AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
The epidemiology of age-related macular degeneration
Klein, R., Peto, T., Bird, A., & Vannewkirk, M. R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.069 · Cited by 932
HTRA1 Promoter Polymorphism in Wet Age-Related Macular Degeneration
DeWan, A., Liu, M., Hartman, S., Zhang, S. S.-M., Liu, D. T. L., Zhao, C., Tam, P. O. S., Chan, W. M., Lam, D. S. C., Snyder, M., et al. (2006) · Science · doi:10.1126/science.1133807 · Cited by 876
Complement C3 variant and the risk of age-related macular degeneration
Yates, J. R. W., Sepp, T., Matharu, B. K., Khan, J. C., Thurlby, D. A., Shahid, H., Clayton, D. G., Hayward, C., Morgan, J., Wright, A. F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072618 · Cited by 829
Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration
Seddon, J. M., Francis, P. J., George, S., Schultz, D. W., Rosner, B., & Klein, M. L. (2007) · JAMA · doi:10.1001/jama.297.16.1793 · Cited by 330
Comparison of Age-related Macular Degeneration Treatments Trials Research, G. (2011) · doi:10.1056/nejmicm1005605 · Cited by 273
Brantley, M. A., Fang, A. M., King, J. M., Tewari, A., Kymes, S. M., & Shiels, A. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.008 · Cited by 201
Ennis, S., Jomary, C., Mullins, R., Cree, A., Chen, X., MacLeod, A., Jones, S., Collins, A., Stone, E., & Lotery, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61348-3 · Cited by 171
Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD
Kloeckener-Gruissem, B., Barthelmes, D., Labs, S., Schindler, C., Kurz-Levin, M., Michels, S., Fleischhauer, J., Berger, W., Sutter, F., & Menghini, M. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6080 · Cited by 120
McKibbin, M., Ali, M., Bansal, S., Baxter, P. D., West, K., Williams, G., Cassidy, F., & Inglehearn, C. F. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.193680 · Cited by 100
Cited by
Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
Finger, R. P., Wickremasinghe, S. S., Baird, P. N., & Guymer, R. H. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.03.009 · Cited by 144
Towards the application of precision medicine in Age-Related Macular Degeneration
Cascella, R., Strafella, C., Caputo, V., Errichiello, V., Zampatti, S., Milano, F., Potenza, S., Mauriello, S., Novelli, G., Ricci, F., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.11.004 · Cited by 76
“Tian et al. (2012), investigated the influence of two VEGFA polymorphisms (rs833069 T/C, rs3025039 C/T) on the drug response after 1-year therapy of three monthly injections, without finding significant associations.”
BackgroundPredicting Non-response to Ranibizumab in Patients with Neovascular Age-related Macular Degeneration
van Asten, F., Rovers, M. M., Lechanteur, Y. T. E., Smailhodzic, D., Muether, P. S., Chen, J., den Hollander, A. I., Fauser, S., Hoyng, C. B., van der Wilt, G. J., et al. (2014) · Ophthalmic Epidemiology · doi:10.3109/09286586.2014.949010 · Cited by 37
Medina, F. M. C., Motta, A. A. L. D., Takahashi, W. Y., Carricondo, P. C., Motta, M. M. D. S., Melo, M. B., & Vasconcellos, J. P. C. (2019) · Ophthalmic Research · doi:10.1159/000475995 · Cited by 12
Metadata
- Authors
- Tian, J., Qin, X., Fang, K., Chen, Q., Hou, J., Li, J., Yu, W., Chen, D., Hu, Y., & Li, X.
- Venue
- Pharmacogenomics
- Publisher
- Informa UK Limited
- Published
- 2012-05
- Volume
- 13
- Issue
- 7
- Pages
- 779-787
- ISSN
- 1462-2416 (ISSN-L)
- 1744-8042
- OpenAlex
- W2080105791
- Cited by
- 44
- References
- 12
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.